Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||Capivasertib + Enzalutamide||Phase I||Actionable||In a Phase I trial, Capivasertib (AZD5363) and Xtandi (enzalutamide) combination treatment was well-tolerated and demonstrated safety, and resulted in an overall response rate of 25% (3/12) in evaluable metastatic castration-resistant prostate cancer patients (n=16) harboring either a PTEN loss or AKT1 E17K (PMID: 32205016; NCT02525068).||32205016|